Format

Send to

Choose Destination
Front Immunol. 2017 Oct 4;8:1203. doi: 10.3389/fimmu.2017.01203. eCollection 2017.

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.

Author information

1
Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
2
Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
3
Tuberculosis Vaccine Initiative (TBVI), Lelystad, Netherlands.
4
Bacteriology Division, MHRA-NIBSC, Potters Bar, United Kingdom.
5
University of Oxford, Oxford, United Kingdom.
6
Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France.
7
Leiden University Medical Center, Leiden, Netherlands.
8
RegExcel Consulting Ltd, Surrey, United Kingdom.
9
Centre Hospital Universitaire Vaudois, Lausanne, Switzerland.
10
University Hospital of Ulm, Ulm, Germany.
11
Biomedical Primate Research Centre, Rijswijk, Netherlands.
12
Public Health England, London, United Kingdom.

Abstract

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

KEYWORDS:

bacille Calmette–Guérin; biomarker; clinical trial; discovery; portfolio management; tuberculosis; vaccination

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center